VEGFC and neoplasm: FOXF2 may promote or inhibit tumour development by affecting the EMT process, G1-S cell cycle transition33,39, Wnt/ beta-catenin pathway33,40–42, BMP/SMAD pathway43, and vascular endothelial growth factor-C (VEGF-C)/vascular growth factor receptor 3 (VEGFR3) pathway44.